These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 142419)

  • 21. Growth hormone and prolactin secretion in liver cirrhosis: evidence for dopaminergic dysfunction.
    Borzio M; Caldara R; Ferrari C; Barbieri C; Borzio F; Romussi M
    Acta Endocrinol (Copenh); 1981 Aug; 97(4):441-7. PubMed ID: 7270004
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of dopaminergic stimulation on growth hormone and prolactin in the treatment of acromegaly].
    Nedvídková J; Felt V
    Vnitr Lek; 1980 Oct; 26(10):988-93. PubMed ID: 7467150
    [No Abstract]   [Full Text] [Related]  

  • 23. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK; Marttila R
    Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Patients with Parkinson disease: functional analysis of dopamine receptors by bromocriptine- thyrotropin-releasing hormone test].
    Díaz F; Liberman C; Chariá P
    Rev Med Chil; 1991 Mar; 119(3):252-7. PubMed ID: 1842116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential ontogeny of opioid, dopaminergic and serotonergic regulation of prolactin secretion.
    Bero LA; Kuhn CM
    J Pharmacol Exp Ther; 1987 Mar; 240(3):825-30. PubMed ID: 3031276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic mediation of beta-endorphin-induced prolactin secretion.
    Van Loon GR; De Souza EB; Shin SH
    Neuroendocrinology; 1980 Oct; 31(4):293-6. PubMed ID: 6252497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dopaminergic blockage using pimozide and dopaminergic stimulation using bromocryptin. Effect on secretion of somatotropin].
    Hainer V; Krejcík L; Urbánek J; Tvaroh F
    Cas Lek Cesk; 1977 Jan; 116(2):11-6. PubMed ID: 576415
    [No Abstract]   [Full Text] [Related]  

  • 28. Neuroendocrine function in Huntington's disease: dopaminergic regulation of prolactin release.
    Caine E; Kartzinel R; Ebert M; Carter AC
    Life Sci; 1978 Mar; 22(10):911-8. PubMed ID: 147978
    [No Abstract]   [Full Text] [Related]  

  • 29. Human growth hormone and dopaminergic drugs, with special reference to deprenyl (selegiline): a summary of studies on volunteers.
    Koulu M; Lammintausta R
    Acta Neurol Scand Suppl; 1983; 95():91-4. PubMed ID: 6428151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberoinfundibular dopaminergic system and anterior pituitary dopamine receptor in Shy-Drager syndrome.
    Konagaya Y; Konagaya M; Takayanagi T
    J Neurol Sci; 1985 Jan; 67(1):93-103. PubMed ID: 3981215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine inhibition of stimulated growth hormone secretion: evidence for dopaminergic modulation of insulin- and L-dopa-induced growth hormone secretion in man.
    Woolf PD; Lantigua R; Lee LA
    J Clin Endocrinol Metab; 1979 Sep; 49(3):326-30. PubMed ID: 468965
    [No Abstract]   [Full Text] [Related]  

  • 32. [Response of hGH to insulin hypoglycemia and to bromocriptine before and after the administration of L-dopa in primary hypothyroidism].
    Campino C; Pumarino H; Michelsen H; Piraino P; Generini G; Bruggendieck B
    Rev Med Chil; 1985 Apr; 113(4):296-300. PubMed ID: 3915142
    [No Abstract]   [Full Text] [Related]  

  • 33. Dopaminergic Modulation of renin activity and aldosterone and prolactin secretion in the spontaneously hypertensive rat.
    Sowers JR; Sollars EG; Tuck ML; Asp ND
    Proc Soc Exp Biol Med; 1980 Sep; 164(4):598-603. PubMed ID: 6997889
    [No Abstract]   [Full Text] [Related]  

  • 34. Phenytoin-induced increase in growth hormone response to levodopa in adult males.
    D'Alessandro R; Cortelli P; Gallassi R; Ghisoli E; Montanaro N; Zoni E; Baruzzi A
    J Neurol Neurosurg Psychiatry; 1984 Jul; 47(7):715-9. PubMed ID: 6431057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulsatile growth hormone and prolactin: effects of (+) butaclamol, a dopamine receptor blocking agent.
    Willoughby JO; Brazeau P; Martin JB
    Endocrinology; 1977 Oct; 101(4):1298-303. PubMed ID: 908278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bromocriptine and dopaminergic function in Huntington disease.
    Loeb C; Roccatagliata G; Albano C; Besio G
    Neurology; 1979 May; 29(5):730-4. PubMed ID: 155784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine receptor sensitivity in the hypothalamus of chronic schizophrenics after haloperidol therapy: growth hormone and prolactin response to stimuli.
    Brambilla F; Bellodi L; Negri F; Smeraldi E; Malagoli G
    Psychoneuroendocrinology; 1979 Oct; 4(4):329-39. PubMed ID: 523590
    [No Abstract]   [Full Text] [Related]  

  • 38. Growth hormone and prolactin secretion in Huntington's disease.
    Levy CL; Carlson HE; Sowers JR; Goodlett RE; Tourtellotte WW; Hershman JM
    Life Sci; 1979 Feb; 24(8):743-9. PubMed ID: 155768
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of apomorphine hydrochloride administration on serum concentrations of prolactin and growth hormone in cattle.
    Gorewit RC
    Experientia; 1981 Feb; 37(2):204-6. PubMed ID: 7238762
    [No Abstract]   [Full Text] [Related]  

  • 40. Relationships between Jenkins Activity Survey scores and responsivity of the dopaminergic system in psychosomatic disorders.
    Sato S; Sugiyama Y; Okuse S; Yashiro N
    Psychother Psychosom; 1987; 48(1-4):7-13. PubMed ID: 3505718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.